Fig. 3: PFS and OS in patients treated with odronextamab, for all patients and by best overall response. | Nature Cancer

Fig. 3: PFS and OS in patients treated with odronextamab, for all patients and by best overall response.

From: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

Fig. 3

a, PFS. b, OS. Data are presented as Kaplan–Meier curves, with tick marks indicating patients with censored data (N = 127 patients; n = 40 with CR, n = 26 with PR). Median values with 95% CIs are presented alongside the respective curves.

Source data

Back to article page